Postmenopausal hormone therapy and lung cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

The latest recommendations on postmenopausal hormone therapy (HT) stress the need first to evaluate the individual benefits and risks and to prescribe the well-informed patient only when the balance is most favorable. As a result of recent studies on the association of lung cancer with HT, this common malignancy was added to the list of potential serious adverse effects of HT. However, data show that estrogen alone does not carry a risk, whereas a combined estrogen + progestin (E + P) regimen may be associated with higher mortality in lung cancer patients. Women usually take HT in the early postmenopausal period and for several years only. No increase in risk was found in E + P users aged 50-59 years, nor for those who used HT for less than 5 years. The absolute numbers involved are in the order of less than one additional case of lung cancer in 1000 woman/years of hormone use.

Original languageEnglish
Pages (from-to)212-214
Number of pages3
JournalClimacteric
Volume14
Issue number2
DOIs
StatePublished - Apr 2011
Externally publishedYes

Keywords

  • Postmenopause
  • hormone therapy
  • lung cancer

Fingerprint

Dive into the research topics of 'Postmenopausal hormone therapy and lung cancer'. Together they form a unique fingerprint.

Cite this